Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma

High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma

Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD

KRdc as induction therapy shows improved OS for NDMM patients

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM